Kristen Hong

Kristen Hong

Auto-generated profile, based on publicly available information

Kristen Hong

Department of Pharmacology, University of Michigan, Ann Arbor (M.Y., K.H.D., A.S.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KHKevin M. Huang
Kevin M. Huang
ALAlix F. Leblanc
Alix F. Leblanc
MUMuhammad Erfan Uddin
Muhammad Erfan Uddin
JKJi Young Kim
Ji Young Kim
MCMingqing Chen
Mingqing Chen
ASAlex Sparreboom
Alex Sparreboom
Peripheral neurotoxicity is a debilitating condition that afflicts up to 90% of patients with colorectal cancer receiving oxaliplatin-containing therapy. Although emerging evidence has highlighted the importance of various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to oxaliplatin-induced peripheral neurotoxicity remains controversial. Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity. The relevance of this transport system was verified in transporter-deficient rats as a secondary model organism, and translational significance of preventive strategies was demonstrated in preclinical models of colorectal cancer. These studies suggest that pharmacological targeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin.

6 December 2021 in EBioMedicine
Verified
Journal Article
Open access
YLYonghong Luo
Yonghong Luo
YGYanhong Guo
Yanhong Guo
HWHuilun Wang
Huilun Wang
MYMinzhi Yu
Minzhi Yu
KHKristen Hong
Kristen Hong
YCY. Eugene Chen
Y. Eugene Chen
Atherosclerosis-related cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Cholesterol crystals (CCs) induce inflammation in atherosclerosis and are associated with unstable plaques and poor prognosis, but no drug can remove CCs in the clinic currently. We generated a phospholipid-based and high-density lipoprotein (HDL)-like nanoparticle, miNano, and determined CC-dissolving capacity, cholesterol efflux property, and anti-inflammation effects of miNano in vitro. Both normal C57BL/6J and Apoe-deficient mice were used to explore the accumulation of miNano in atherosclerotic plaques. The efficacy and safety of miNano administration to treat atherosclerosis were evaluated in the Ldlr-deficient atherosclerosis model. The CC-dissolving capacity of miNano was also detected using human atherosclerotic plaques ex vivo. We found that miNano bound to and dissolved CCs efficiently in vitro, and miNano accumulated in atherosclerotic plaques, co-localized with CCs and macrophages in vivo. Administration of miNano inhibited atherosclerosis and improved plaque stability by reducing CCs and macrophages in Ldlr-deficient mice with favorable safety profiles. In macrophages, miNano prevented foam cell formation by enhancing cholesterol efflux and suppressed inflammatory responses via inhibiting TLR4-NF-κB pathway. Finally, in an ex vivo experiment, miNano effectively dissolved CCs in human aortic atherosclerotic plaques. Together, our work finds that phospholipid-based and HDL-like nanoparticle, miNano, has the potential to treat atherosclerosis by targeting CCs and stabilizing plaques. This work was supported by the National Institutes of Health HL134569, HL109916, HL136231, and HL137214 to Y.E.C, HL138139 to J.Z., R21NS111191 to A.S., by the American Heart Association 15SDG24470155, Grant Awards (U068144 from Bio-interfaces and G024404 from M-BRISC) at the University of Michigan to Y.G., by the American Heart Association 19PRE34400017 and Rackham Helen Wu award to M.Y., NIH T32 GM07767 to K. H., Barbour Fellowship to D.L.

4 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
HHHongliang He
Hongliang He
RAReheman Adili
Reheman Adili
LLLisha Liu
Lisha Liu
KHKristen Hong
Kristen Hong
MHMichael Holinstat
Michael Holinstat
ASAnna Schwendeman
Anna Schwendeman
SHDL is a promising antithrombotic agent delivery system due to its antithrombotic effect itself and improved drug delivery.

1 April 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
YLYaozhong Liu
Yaozhong Liu
MYMinzhi Yu
Minzhi Yu
HWHuilun Wang
Huilun Wang
KDKristen Hong Dorsey
Kristen Hong Dorsey
YCYalun Cheng
Yalun Cheng
YGYanhong Guo
Yanhong Guo
BACKGROUND: Abdominal aortic aneurysm (AAA) is a complex vascular pathology without pharmaceutical interventions. This study aimed to evaluate whether restoring vascular smooth muscle cell (VSMC) mitochondrial function could prevent AAA development. METHODS: Ang II (angiotensin II)–induced AAA was established in Ldlr -deficient mice, and the gene expression profiles in abdominal aortic tissues exhibiting varying degrees of severity were analyzed. Synthetic high-density lipoprotein (sHDL) formulated with Apoa1 mimetic peptide and phospholipids was evaluated for the protective effects on VSMC mitochondria. The therapeutic efficacy of sHDL was further investigated in Ang II–infusion and PPE (porcine pancreatic elastase)-induced AAA models. RESULTS: VSMC mitochondrial damage intensified gradually during AAA development, which was confirmed in distinct AAA animal models and human tissues. sHDL accumulated in the aneurysmatic lesions and restored mitochondrial DNA levels and the expression of genes related to oxidative phosphorylation following Ang II infusion. In mouse primary VSMCs, sHDL maintained mitochondrial homeostasis by suppressing the upregulation of DRP1 (dynamin-related protein 1), a protein involved in mitochondrial fission, reducing the generation of reactive oxygen species, preventing the loss of mitochondrial membrane potential, and preserving mitochondrial respiratory capacity. Administration of sHDL decreased Ang II–induced AAA incidence (control versus treatment, 76% versus 40%; P <0.05) and maximum aortic diameters. The protective effects of sHDL were further validated in the PPE model, with reductions observed in maximum aortic diameters and aortic mitochondrial DNA loss. Post-Ang II infusion, administration of sHDL improved VSMC mitochondrial function and suppressed aneurysm growth in Apoe-deficient mice. Human AAA is characterized by mitochondrial dysfunction, and liver-derived HDL (high-density lipoprotein) components play a pivotal role in regulating gene expression in aortic tissues. CONCLUSIONS: VSMC mitochondrial damage is a pivotal factor in the development of AAA. The utilization of sHDL nanoparticles represents a promising novel therapeutic approach for AAA, aimed at restoring VSMC mitochondrial function.

14 July 2021 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
HHHongliang He
Hongliang He
KHKristen Hong
Kristen Hong
LLLisha Liu
Lisha Liu
ASAnna Schwendeman
Anna Schwendeman